Neddylation Pathway Dynamics in Cancer Therapeutics

Neddylation, the covalent attachment of the ubiquitin-like protein NEDD8 to substrate lysines, orchestrates key aspects of protein homeostasis by modulating the activity of cullin-based E3 ubiquitin ligases (CRLs) and a growing list of non-cullin targets. In cancer, hyperactivation of the neddylation cascade—mediated by the sequential action of NEDD8-activating enzyme (E1), conjugating enzymes (E2), and ligases (E3)—drives aberrant degradation of cell-cycle regulators, DNA-damage sensors and signalling adaptors. Small-molecule inhibitors that block NEDD8 activation or disrupt accessory interactions have shown preclinical efficacy by stabilising tumour-suppressive substrates, triggering apoptotic and senescence pathways, and reprogramming the tumour microenvironment. Recent advances reveal that selective interference with neddylation not only impairs tumour cell proliferation but can also enhance antitumour immunity when combined with immune-checkpoint blockade. Structural and mechanistic studies of pathway components have informed the design of highly specific probes capable of discriminating individual cullin neddylation events. Collectively, these insights underscore the therapeutic promise of precision targeting within the neddylation network for diverse cancer types, and point to emerging strategies to overcome resistance and to extend application to fibrotic and metabolic disorders.

Research from Nature Portfolio

Recent studies have revealed that loss of NEDD8 in triple-negative breast cancer cells creates a conditional vulnerability to PD-1 blockade. Genome-wide CRISPR screens in co-culture systems demonstrated that NEDD8-deficient tumours regain sensitivity to nivolumab, provoking CD8+ T-cell-mediated regression in immunocompetent models. Mechanistic follow-up indicated that absence of NEDD8 heightens antigen presentation and pro-inflammatory signalling without causing long-term proliferative deficits, thus positioning NEDD8 as a synergistic target for checkpoint immunotherapy. Another line of investigation has harnessed structural biology to develop DI-591, a potent inhibitor of the DCN1–UBC12 interface. DI-591 selectively blocks neddylation of cullin 3 by occluding the scaffolding interaction required for E2 recruitment, without perturbing other cullin family members. Cellular profiling confirmed conversion of cullin 3 to its un-neddylated state, leading to stabilisation of specific substrates and growth inhibition in cancer cell lines. This probe compound validates cullin-specific intervention as a route toward tailored neddylation modulators.

Neddylation Pathway Dynamics in Cancer Therapeutics publication trend

The graph below shows the total number of articles in neddylation pathway dynamics in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Neddylation: Post-translational modification in which NEDD8 is enzymatically conjugated to lysine residues on target proteins.

NEDD8-activating enzyme (NAE): E1 enzyme that adenylates NEDD8 and forms a thioester intermediate to initiate the neddylation cascade.

Cullin-RING ligases (CRLs): Largest family of E3 ubiquitin ligases whose activity is activated by cullin neddylation and reversed by the COP9 signalosome.

DCN1–UBC12 interaction: Scaffolding interface between the DCN1 protein and the E2 enzyme UBC12, essential for productive cullin neddylation.

Immune checkpoint blockade: Therapeutic strategy that inhibits regulatory pathways (e.g., PD-1/PD-L1) to enhance T-cell-mediated antitumour responses.

References

1. Protein neddylation and its role in health and diseases. Signal Transduction and Targeted Therapy (2024).
2. Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions. Journal of Hematology & Oncology (2023).
3. Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer. Nature Communications (2024).
4. Targeting cullin neddylation for cancer and fibrotic diseases. Theranostics (2023).
5. Neddylation: a novel modulator of the tumor microenvironment. Molecular Cancer (2019).
6. A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation. Nature Communications (2017).